Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks
Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks Therapeutics.
Speculation surrounding a potential transaction between the two companies first emerged on 10 February 2025, when Reuters reported that Merck KGaA was engaged in discussions to acquire SpringWorks. The same day, Merck KGaA acknowledged the negotiations, but stressed that there was no certainty a deal would be finalised. SpringWorks' stock price surged by 34% following the disclosure of the discussions, pushing its market capitalisation over $4bn.
During a 6 March press call, Merck KGaA's CEO Belén Garijo stated that there 'is very little that we can say at this time,' regarding the ongoing talks.
A successful acquisition would provide Merck KGaA with SpringWorks' portfolio of targeted oncology therapies, including Ogsiveo (nirogacestat), which is approved for desmoid treating tumours, as well as the MEK inhibitor Gomekli (mirdametinib), which was recently approved in February 2025 for treating neurofibromatosis type 1 (NF1), a rare genetic disorder.
According to GlobalData's Pharma Intelligence Center, Gomekli is projected to generate up to $564m in global sales by 2030, while Ogsiveo sales are expected to reach $1.2bn by the same year.
GlobalData is the parent company of Pharmaceutical Technology.
Garijo emphasised that Merck KGaA's broader merger and acquisition (M&A) strategy remains focused on targeted, lower-risk deals aimed at strengthening its life sciences and healthcare portfolio, particularly through late-stage in-licencing opportunities.
'This is going to be absolutely limited to clear cut, low risk deals that will create value from very early on. So rest assured, we will fully comply with this and stay extremely disciplined when executing our M&A agenda,' said Garijo in a call to investors.
The company's healthcare division reported 7% net sales growth in 2024, reaching €8.5bn ($9.2bn). Oncology was a key driver of this performance, with sales in the segment increasing by 12.7% to €2bn ($2.17bn). The company has made moves in the oncology space in recent years, including an October 2024 acquisition of Modifi Biosciences, a Yale University-spinout focused on DNA repair-targeting cancer therapies. Merck KGaA acquired all outstanding shares of Modifi through a subsidiary for an upfront payment of $30m, with the potential for additional milestone payments totalling up to $1.3bn.
Merck KGaA's top-selling product in 2024 was Erbitux (cetuximab), which generated €1.16bn ($1.25bn) in revenue. The drug – a monoclonal antibody used in the treatment of certain head and neck cancers as well as colorectal cancer – is expected to see continued sales growth, with GlobalData's projections estimating it could generate $1.9bn in annual revenue by 2030.
"Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Chicken Salad Chick to open ten new restaurants in Minneapolis
US-based fast casual restaurant Chicken Salad Chick is broadening its footprint in the Midwest with ten new restaurants in the Minneapolis area. This is a significant step for the brand as it introduces its dining experience to the Upper Midwest. The Coffey family, with a basketball legacy, is behind the signed agreement that will bring the franchise to the region. Richard Coffey said: "We knew we wanted to go into business with a brand that we could all get behind. "Chicken Salad Chick stood out because of the support and communication we've received from the team. This is more than a business venture, it's a family journey, and we're excited to do it with a brand that feels the same way." The brand's strategic growth plan includes opening the ten locations before 2030, targeting development in Hennepin and Ramsey County. With an open real estate landscape, Chicken Salad Chick sees opportunities for market growth in the Midwest. Franchise development vice-president Mark Verges stated: "We're thrilled to have a passionate and community-driven family join Chicken Salad Chick. "Their deep roots in Minnesota and commitment to giving back make them great partners as we grow our presence in the Midwest." Chicken Salad Chick is leveraging the momentum from 2024, aiming to set new records with franchise deals across the US in 2025. The franchise development team has identified Illinois, Iowa, Michigan, Minnesota, Ohio, Pennsylvania, West Virginia and Wisconsin as key areas for growth. The brand has experienced a 13% increase in unit count year-on-year and reports more than $400m in system-wide sales, a 56% increase over 2021, with an average unit volume (AUV) of $1.48m, according to its 2024 franchise disclosure document (FDD). In addition to the Midwest expansion, Chicken Salad Chick recently announced plans to increase its presence in Texas with a new outlet in Temple. "Chicken Salad Chick to open ten new restaurants in Minneapolis" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
UK SMEs defy economic pressures with strong growth: research
New research from specialist SME lender Shawbrook reveals that 71% of SMEs have grown in the last 12 months, with 21% experiencing significant growth. This marks a sharp increase from 2024, when only 46% reported growth and just 13% saw significant expansion. Larger SMEs, those with between 100 and 249 employees, are performing particularly well, with 76% reporting growth, up from 49% the previous year. The positive trajectory is being driven by a combination of strong customer demand (32%), team expansion (29%), and investment in staff (27%). These trends suggest that SMEs are taking a proactive stance, prioritising internal capability and customer relationships in the face of ongoing external pressures such as inflation, higher wages, and regulatory uncertainty. Looking ahead, many SMEs are planning to keep the momentum going. Almost half (48%) intend to upskill staff, 25% plan to hire new employees, and 22% are set to invest in premises upgrades. These plans point to a sector focused not just on survival, but on long-term growth and competitiveness. Neil Rudge, Chief Banking Officer, Commercial at Shawbrook, said: 'It's great to see so many businesses not just holding steady in tough conditions but actually growing and investing in their future. Politicians love to talk about growth – but it's Britain's SMEs that actually deliver it. They don't need more speeches, they need real backing: fair tax, smart policy and access to funding that helps them build, hire and grow.' He added that the findings are a powerful reminder of the vital role SMEs play in the UK economy: 'Even with wider pressures like the risk of a trade war and rising costs from things like minimum wage and National Insurance hikes, UK SMEs are proving themselves to be dynamic, resilient, and crucial to economic health. While big business grabs headlines, it's SMEs that keep the UK running—creating jobs, paying taxes and powering local economies.' As the labour market begins to open up and economic conditions evolve, SMEs are positioned to play a key role in recovery and growth. The research points to a sector that's not just weathering the storm but actively investing in people and capacity—laying the groundwork for a more resilient and dynamic future. "UK SMEs defy economic pressures with strong growth: research" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
a day ago
- Yahoo
Avicenna.ai scoops CE marks for two AI fracture detection tools
French artificial intelligence (AI)-based medical imaging company has secured CE marks for a pair of radiologic screening tools to detect fractures from CT scans. CINA-VCF Quantix is an AI algorithm is used to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions, while CINA-CSpine is designed for the detection and triage of cervical spine fractures. Both tools gained 510(k) clearance from the US Food and Drug Administration (FDA) in 2024, while the tools' receipt of CE mark follows clearance on five other AI tools in 2024 under the EU's Medical Device Regulation (EU MDR). For use in patients aged 50 and above who are undergoing patients undergoing CT scans of the chest or abdomen for other conditions, CINA-VCF Quantix automatically labels vertebrae and calculates vertebral height loss ratios in the thoracic and lumbar spine. In cases where a vertebral height loss ratio exceeds 20%–25%, a figure indicative of a moderate- to severe VCF, the algorithm generates prompts notifying radiologists to report their early findings in support of proactive patient care, Avicenna stated. co-founder and CEO, Cyril Di Grandi commented: "Osteoporotic vertebral fractures can have a profound impact on patients' quality of life. "By encouraging the reporting of VCF presence and severity, CINA-VCF Quantix has the potential to make a real difference in long-term patient outcomes." CINA-CSpine is designed to automatically flag suspected acute cervical spine fractures through radiologists' existing systems. Di Grandi continued: "The launch of CINA-CSpine in the European market marks a significant step forward in trauma care. By reducing the time between scan and diagnosis, we're helping radiologists catch cervical spine fractures faster and more reliably.' A 2023 report on AI in healthcare by GlobalData forecasts that global revenue for AI platforms across the sector will reach a valuation of almost $19bn by 2027, with the radiology field seeing some of the highest implementation of AI technologies. Research indicates that thoracolumbar fusion procedures, one of the most common spine surgery types, are in growing demand, with thoracolumbar procedures such as anterior lumbar interbody fusion (ALIF) and posterior lumbar fusion (PLF) in the US projected to see respective rises from 46,903 to 55,528 and 248,416 to 297,994 between 2020 and 2040. According to GlobalData, the spinal fusion market segment, of which thoracolumbar fusion is a part, is growing at a CAGR of 2.3% and forecast to reach a valuation of around $11.23bn by 2033. " scoops CE marks for two AI fracture detection tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
